Open AccessFangchinoline induces gallbladder cancer cell apoptosis by suppressing PI3K/Akt/XIAP axis
Author(s) -
Jiandong Li,
Wenda Cen,
Chenhao Tong,
Luna Wang,
Weiguang Zhang,
Shiqing Deng,
Jianhua Yu,
Baochun Lu
Publication year - 2022
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0266738
Subject(s) - pi3k/akt/mtor pathway , xiap , apoptosis , cancer research , protein kinase b , in vivo , gallbladder cancer , cell growth , cancer , flow cytometry , gallbladder , tunel assay , medicine , biology , chemistry , programmed cell death , immunology , caspase , biochemistry , genetics , microbiology and biotechnology
Gallbladder cancer (GBC) is the most common biliary tract malignancy with a dismal prognosis. The development of new drugs may help to improve prognosis. This study found that fangchinoline, a bisbenzylisoquinoline alkaloids, inhibited the proliferation and clone formation of GBC cells in a dose-dependent manner. Moreover, Hoechst staining, TUNEL assays, and flow cytometry demonstrated that fangchinoline effectively induced apoptosis in GBC cells. Further studies found that an anti-apoptotic pathway, the PI3K/Akt/XIAP axis, was significantly inhibited in GBC cells after treating with fangchinoline. Finally, we confirmed that fangchinoline restrained xenograft tumor growth in vivo. Our findings indicate that fangchinoline can be considered a potential drug for GBC treatment.